Advertisement

Wiener klinische Wochenschrift

, Volume 131, Issue 7–8, pp 188–189 | Cite as

MUW researcher of the month

  • Claudia D. Fuchs-SteinerEmail author
MUW researcher of the month
  • 7 Downloads

Notes

Literatur

  1. 1.
    Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlstrom A, et al. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(-/-) mice by modulating composition, signalling and excretion of faecal bile acids. Gut. 2018;67:1683–91. IF:17,02.CrossRefGoogle Scholar
  2. 2.
    Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, Oude Elferink RPJ, et al. Na(+) -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. Hepatology. 2018. IF:14,08.  https://doi.org/10.1002/hep.29888 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Baghdasaryan A, Fuchs CD, Osterreicher CH, Lemberger UJ, Halilbasic E, Pahlman I, Graffner H, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2016;64:674–81. IF:15,04.CrossRefGoogle Scholar
  4. 4.
    Fuchs CD, Paumgartner G, Wahlstrom A, Schwabl P, Reiberger T, Leditznig N, Stojakovic T, et al. Metabolic preconditioning protects BSEP/ABCB11(-/-) mice against cholestatic liver injury. J Hepatol. 2017;66:95–101. IF:15,04.CrossRefGoogle Scholar
  5. 5.
    Lemberger UJ, Fuchs CD, Schofer C, Bileck A, Gerner C, Stojakovic T, Taketo MM, et al. Hepatocyte specific expression of an oncogenic variant of beta-catenin results in lethal metabolic dysfunction in mice. Oncotarget. 2018;9:11243–57. IF:5,20.CrossRefGoogle Scholar
  6. 6.
    Lemberger UJ, Fuchs CD, Karer M, Haas S, Stojakovic T, Schofer C, Marschall HU, et al. Hepatocyte specific expression of an oncogenic variant of beta-catenin results in cholestatic liver disease. Oncotarget. 2016;7:86985–98. IF:5,20.CrossRefGoogle Scholar
  7. 7.
    Blokker BA, Maijo M, Echeandia M, Galduroz M, Patterson AM, Ten A, Philo M, et al. Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease. Hepatology. 2018. IF:14,08.  https://doi.org/10.1002/hep.30275 CrossRefGoogle Scholar
  8. 8.
    Sombetzki M, Fuchs CD, Fickert P, Osterreicher CH, Mueller M, Claudel T, Loebermann M, et al. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol. 2015;62:871–8. IF:15,04.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Klinische Abteilung für Gastroenterologie und HepatologieMedizinische Universität Wien, Universitätsklinik für Innere Medizin IIIWienAustria

Personalised recommendations